000			01626 a2200469 4500
005			20250516051708.0
264		0	_c20120813
008			201208s 0 0 eng d
022			_a1520-5711
024	7		_a10.1080/10543406.2011.590922 _2doi
040			_aNLM _beng _cNLM
100	1		_aHatfield, Laura A
245	0	0	_aJoint modeling of multiple longitudinal patient-reported outcomes and survival. _h[electronic resource]
260			_bJournal of biopharmaceutical statistics _cSep 2011
300			_a971-91 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAntimetabolites, Antineoplastic _xtherapeutic use
650	0	4	_aBayes Theorem
650	0	4	_aClinical Trials, Phase III as Topic _xmethods
650	0	4	_aDisease Progression
650	0	4	_aDisease-Free Survival
650	0	4	_aGlutamates _xtherapeutic use
650	0	4	_aGuanine _xanalogs & derivatives
650	0	4	_aHumans
650	0	4	_aLongitudinal Studies
650	0	4	_aMesothelioma _xdrug therapy
650	0	4	_aModels, Statistical
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aPemetrexed
650	0	4	_aResearch Design
650	0	4	_aResearch Report
650	0	4	_aSelf Report
650	0	4	_aSurvival Analysis
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aUnited States
650	0	4	_aUnited States Food and Drug Administration
700	1		_aBoye, Mark E
700	1		_aCarlin, Bradley P
773	0		_tJournal of biopharmaceutical statistics _gvol. 21 _gno. 5 _gp. 971-91
856	4	0	_uhttps://doi.org/10.1080/10543406.2011.590922 _zAvailable from publisher's website
999			_c21075526 _d21075526